Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOTUM448 is a plant-based, polyphenol-rich active substance developed by Valbiotis as a non-drug preventive approach for metabolic dysfunction-associated steatotic liver disease (MASLD), including non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is a patented combination of five plant extracts and choline. The formulation is designed to target hepatic steatosis, inflammation, and fibrosis. Its mechanism of action involves the modulation of the gut microbiota and the reduction of pro-inflammatory macrophage recruitment to the liver, while preserving tissue-resident Kupffer cells. Preclinical data indicate that TOTUM448 improves metabolic parameters, including insulin sensitivity and glucose tolerance, and reduces fat accumulation in the liver.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TOTUM448.